Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia

Schizophrenia Research

Volumn 140, Issue 1-3, 2012, Pages 122-128

  Bartzokis, George ^a,b,c   Lu, Po H ^b   Raven, Erika P ^a,c   Amar, Chetan P ^a,c   Detore, Nicole R ^a   Couvrette, Alexander J ^a,c   Mintz, Jim ^d   Ventura, Joseph ^a   Casaus, Laurie R ^a   Luo, John S ^a   Subotnik, Kenneth L ^a   Nuechterlein, Keith H ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Antipsychotic; Atypical; Development; Dopamine; Gray matter; Medication; Myelin; Oligodendrocyte; Second generation; White matter

Indexed keywords

RISPERIDONE;

ADULT; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FRONTAL LOBE; HUMAN; MALE; MYELINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; FRONTAL LOBE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; NERVE FIBERS, MYELINATED; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84865322948     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.06.036     Document Type: Article

References (77)

1. Alaerts M., Ceulemans S., Forero D., Moens L.N., De Zutter S., Heyrman L., et al. Support for NRG1 as a susceptibility factor for schizophrenia in a northern Swedish isolated population. Arch. Gen. Psychiatry 2009, 66:828-837.
2. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS) 1984, The University of Iowa, Iowa City, IA.
3. Andreasen N.C. The Scale for the Assessment of Positive Symptoms (SAPS) 1984, The University of Iowa, Iowa City.
4. Aston C., Jiang L., Sokolov B.P. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J. Neurosci. Res. 2004, 77:858-866.
5. Azim K., Butt A.M. GSK3beta negatively regulates oligodendrocyte differentiation and myelination in vivo. Glia 2011, 59:540-553.
6. Bai Y.M., Ting Chen T., Chen J.Y., Chang W.H., Wu B., Hung C.H., et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J. Clin. Psychiatry 2007, 68:1218-1225.
7. Barkovich A.J., Lyon G., Evrard P. Formation, maturation, and disorders of white matter. AJNR Am. J. Neuroradiol. 1992, 13:447-461.
8. Bartzokis G. Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. Neuropsychopharmacology 2002, 27:672-683.
9. Bartzokis G. Neuroglialpharmacology: white matter pathophysiologies and psychiatric treatments. Front. Biosci. 2011, 16:2695-2733.
10. Bartzokis G. Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments. Neuropharmacology 2012, 62:2137-2153.
11. Bartzokis G., Altshuler L.L. Biological underpinnings of treatment resistance in schizophrenia: an hypothesis. Psychopharmacol. Bull. 2003, 37:5-7.
12. Bartzokis G., Altshuler L. Reduced intracortical myelination in schizophrenia. Am. J. Psychiatry 2005, 162:1229-1230.
13. Bartzokis G., Beckson M., Lu P.H., Nuechterlein K.H., Edwards N., Mintz J. Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study. Arch. Gen. Psychiatry 2001, 58:461-465.
14. Bartzokis G., Nuechterlein K.H., Lu P.H., Gitlin M., Rogers S., Mintz J. Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study. Biol. Psychiatry 2003, 53:412-421.
15. Bartzokis G., Lu P.H., Nuechterlein K.H., Gitlin M., Doi C., Edwards N., et al. Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia. Schizophr. Res. 2007, 93:13-22.
16. Bartzokis G., Lu P.H., Stewart S.B., Oluwadara B., Lucas A.J., Pantages J., et al. In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophr. Res. 2009, 113:322-331.
17. Bartzokis G., Lu P.H., Amar C.P., Raven E.P., DeTore N.R., Altshuler L.L., et al. Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr. Res. 2011, 132:35-41.
18. Bartzokis G., Lu P.H., Raven E.P., Amar C.P., DeTore N.R., Altshuler L.L., et al. Abnormal Trajectory of Intracortical Myelination in Schizophrenia Implicates White Matter in Pathophysiology and Antipsychotic Mechanism of Action. Schizophr. Res. 2012.
19. Beasley C.L., Honavar M., Everall I.P., Cotter D. Two-dimensional assessment of cytoarchitecture in the superior temporal white matter in schizophrenia, major depressive disorder and bipolar disorder. Schizophr. Res. 2009, 115:156-162.
20. Beaulieu J.M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011, 63:182-217.
21. Blasi G., Napolitano F., Ursini G., Taurisano P., Romano R., Caforio G., et al. DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1158-1163.
22. Boter H., Peuskens J., Libiger J., Fleischhacker W.W., Davidson M., Galderisi S., et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr. Res. 2009, 115:97-103.
23. Chambers J.S., Perrone-Bizzozero N.I. Altered myelination of the hippocampal formation in subjects with schizophrenia and bipolar disorder. Neurochem. Res. 2004, 29:2293-2302.
24. Chandran P., Upadhyay J., Markosyan S., Lisowski A., Buck W., Chin C.L., et al. Magnetic resonance imaging and histological evidence for the blockade of cuprizone-induced demyelination in C57BL/6 mice. Neuroscience 2012, 202:446-453.
25. Cocchi L., Walterfang M., Testa R., Wood S.J., Seal M.L., Suckling J., et al. Grey and white matter abnormalities are associated with impaired spatial working memory ability in first-episode schizophrenia. Schizophr. Res. 2009, 115:163-172.
26. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Erlbaum Associates, Hillsdale, NJ.
27. Emsley R., Rabinowitz J., Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr. Res. 2007, 89:129-139.
28. Flynn S.W., Lang D.J., Mackay A.L., Goghari V., Vavasour I.M., Whittall K.P., et al. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol. Psychiatry 2003, 8:811-820.
29. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. PNAS 2001, 98:4746-4751.
30. Ho B.C., Andreasen N.C., Nopoulos P., Arndt S., Magnotta V., Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch. Gen. Psychiatry 2003, 60:585-594.
31. Hof P.R., Haroutunian V., Copland C., Davis K.L., Buxbaum J.D. Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochem. Res. 2002, 27:1193-1200.
32. Hof P.R., Haroutunian V., Friedrich V.L., Byne W., Buitron C., Perl D.P., et al. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol. Psychiatry 2003, 53:1075-1085.
33. Howes O.D., Bose S.K., Turkheimer F., Valli I., Egerton A., Valmaggia L.R., et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am. J. Psychiatry 2011, 168:1311-1317.
34. Jaaro-Peled H., Hayashi-Takagi A., Seshadri S., Kamiya A., Brandon N.J., Sawa A. Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends Neurosci. 2009, 32:485-495.
35. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
36. Katsel P., Davis K.L., Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: A gene ontology study. Schizophr. Res. 2005, 79:157-173.
37. Keith S. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Expert. Rev. Neurother. 2009, 9:9-31.
38. Kemper T. Neuroanatomical and neuropathological changes during aging and dementia. Clinical Neurology of Aging 1994, 3-67. Oxford University Press, New York. 2nd ed. M. Albert, J. Knoefel (Eds.).
39. Koenig S.H. Cholesterol of myelin is the determinant of gray-white contrast in MRI of brain. Magn. Reson. Med. 1991, 20:285-291.
40. Le-Niculescu H., Balaraman Y., Patel S., Tan J., Sidhu K., Jerome R.E., et al. Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B:129-158.
41. Lieberman J.A. Neurobiology and the natural history of schizophrenia. J. Clin. Psychiatry 2006, 67:e14.
42. Lieberman J., Jody D., Geisler S., Alvir J., Loebel A., Szymanski S., et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry 1993, 50:369-376.
43. Lieberman J., Chakos M., Wu H., Alvir J., Hoffman E., Robinson D., et al. Longitudinal study of brain morphology in first episode schizophrenia. Biol. Psychiatry 2001, 49:487-499.
44. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 2001, 50:884-897.
45. Lindenmayer J.P., Liu-Seifert H., Kulkarni P.M., Kinon B.J., Stauffer V., Edwards S.E., et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J. Clin. Psychiatry 2009, 70:990-996.
46. Martins-de-Souza D. Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia. J. Psychiatr. Res. 2010, 44:149-156.
47. Nuechterlein K.H., Dawson M.E., Gitlin M., Ventura J., Goldstein M.J., Snyder K.S., et al. Developmental processes in schizophrenic disorders: longitudinal studies of vulnerability and stress. Schizophr. Bull. 1992, 18:387-425.
48. Nuechterlein K.H., Miklowitz D.J., Ventura J., Gitlin M.J., Stoddard M., Lukoff D. Classifying episodes in schizophrenia and bipolar disorder: criteria for relapse and remission applied to recent-onset samples. Psychiatry Res. 2006, 144:153-166.
49. Nuechterlein K.H., Subotnik K.L., Turner L.R., Ventura J., Becker D.R., Drake R.E. Individual placement and support for individuals with recent-onset schizophrenia: integrating supported education and supported employment. Psychiatr. Rehabil. J. 2008, 31:340-349.
50. O'Brien J.S., Sampson E.L. Lipid composition of the normal human brain: gray matter, white matter, and myelin. J. Lipid Res. 1965, 6:537-544.
51. Olivares J.M., Peuskens J., Pecenak J., Resseler S., Jacobs A., Akhras K.S. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr. Med. Res. Opin. 2009, 25:2197-2206.
52. Olivares J.M., Rodriguez-Morales A., Diels J., Povey M., Jacobs A., Zhao Z., et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur. Psychiatry 2009, 24:287-296.
53. Parlapani E., Schmitt A., Erdmann A., Bernstein H.G., Breunig B., Gruber O., et al. Association between myelin basic protein expression and left entorhinal cortex pre-alpha cell layer disorganization in schizophrenia. Brain Res. 2009, 1301:126-134.
54. Robinson D.G., Woerner M.G., Alvir J.M., Geisler S., Koreen A., Sheitman B., et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 1999, 156:544-549.
55. Robinson D.G., Woerner M.G., McMeniman M., Mendelowitz A., Bilder R.M. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 2004, 161:473-479.
56. Rouser G., Kritchevsky G., Yamamoto A., Baxter C.F. Lipids in the nervous system of different species as a function of age: brain, spinal cord, peripheral nerve, purified whole cell preparations, and subcellular particulates: regulatory mechanisms and membrane structure. Adv. Lipid Res. 1972, 10:261-360.
57. Saher G., Brugger B., Lappe-Siefke C., Mobius W., Tozawa R., Wehr M.C., et al. High cholesterol level is essential for myelin membrane growth. Nat. Neurosci. 2005, 8:468-475.
58. Saravanan B., Jacob K.S., Johnson S., Prince M., Bhugra D., David A.S. Outcome of first-episode schizophrenia in India: longitudinal study of effect of insight and psychopathology. Br. J. Psychiatry 2010, 196:454-459.
59. Schmitt A., Steyskal C., Bernstein H.G., Schneider-Axmann T., Parlapani E., Schaeffer E.L., et al. Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol. 2009, 117:395-407.
60. Seeman P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin. Schizophr. Relat. Psychoses 2010, 4:56-73.
61. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatry 1995, 52:805-818. discussion 819-20.
62. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J. Comp. Neurol. 1998, 392:402-412.
63. Selemon L.D., Lidow M.S., Goldman-Rakic P.S. Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure. Biol. Psychiatry 1999, 46:161-172.
64. Spencer K.M., Nestor P.G., Perlmutter R., Niznikiewicz M.A., Klump M.C., Frumin M., et al. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17288-17293.
65. Subotnik K.L., Nuechterlein K.H., Ventura J., Gitlin M.J., Marder S.R., Mintz J., et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am. J. Psychiatry 2011, 168:286-292.
66. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 2004, 67:269-275.
67. Uranova N.A., Vikhreva O.V., Rachmanova V.I., Orlovskaya D.D. Ultrastructural alterations of myelinated fibers and oligodendrocytes in the prefrontal cortex in schizophrenia: a postmortem morphometric study. Schizophr. Res.Treat. 2011.
68. Valk J., van der Knaap M.S. Magnetic Resonance of Myelin, Myelination, and Myelin Disorders 1989, Spring-Verlag, New York.
69. van der Knaap M.S., Valk J. MR imaging of the various stages of normal myelination during the first year of life. Neuroradiology 1990, 31:459-470.
70. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry 2009, 70(Suppl. 4):1-46. quiz 47-8.
71. Ventura J., Liberman R.P., Green M.F., Shaner A., Mintz J. Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Res. 1998, 79:163-173.
72. Vostrikov V., Uranova N. Age-related increase in the number of oligodendrocytes is dysregulated in schizophrenia and mood disorders. Schizophr. Res.Treat. 2011, Article ID 174689, 10 pages. http://dx.doi.org/10.1155/2011/174689.
73. Vostrikov V.M., Uranova N.A., Orlovskaya D.D. Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr. Res. 2007, 94:273-280.
74. Wang H., Xu H., Niu J., Mei F., Li X., Kong J., et al. Haloperidol activates quiescent oligodendroglia precursor cells in the adult mouse brain. Schizophr. Res. 2010, 119:164-174.
75. Whitford T.J., Grieve S.M., Farrow T.F., Gomes L., Brennan J., Harris A.W., et al. Volumetric white matter abnormalities in first-episode schizophrenia: a longitudinal, tensor-based morphometry study. Am. J. Psychiatry 2007, 164:1082-1089.
76. Willis M., Svensson M., Lothgren M., Eriksson B., Berntsson A., Persson U. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur. J. Health Econ. 2010, 11:585-594.
77. Xu H., Yang H.J., McConomy B., Browning R., Li X.M. Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: effects of antipsychotics. Front. Behav. Neurosci. 2010, 4:8.